Video Library

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems. Please feel free to offer comments and raise questions in our Discussion Forums

Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy. Please feel free to offer comments and raise questions in our Discussion Forums. Transcript I see a number of

Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.

For our 5th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the most appropriate treatment for elderly patients with advanced NSCLC, and whether age alters the recommendations.

Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank

For our 7th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the best treatment for frail patients with advanced NSCLC.

For our 17th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss first line therapy for NSCLC patients that have anaplastic lymphoma kinase (ALK) positive.

For our 18th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss acquired resistance to targeted therapies: biology and different clinical patterns.